Committee to Restore Nymox Shareholder Value Challenges Nymox CEO Averback to Publish 2022 FDA Refusal To File Correspondence Received May 10, 2022
27.7.2023 18:15:00 EEST | Business Wire | Press release
The Committee to Restore Nymox Shareholder Value, LLC (CRNSV), with a goal to recover shareholder value in NYMOX PHARMACEUTICAL CORP ("NYMX-Q"), today challenges the Company to publish a rarely issued Refusal to File (RTF) Letter from the US Food and Drug Administration (FDA) in the pursuit of full transparency and in the interests of all shareholders. Investors will then be able to determine how close the Company’s lead product is to being approved in the critical US market for the purpose of treating Benign Prostatic Hyperplasia (BPH), as well as the claimed cancer treatment, as outlined in the recent press releases which recycled old news.
CRNSV believes this will highlight the failure of Nymox management to properly present this data to the FDA, which formally denied review of the New Drug Application (NDA) in a rarely issued RTF letter. It will refute recent statements regarding keyman status when the results are read.
Chris Riley, one of the founding members of CRNSV, says, “These veiled inferences and questionable tactics, including intimidating threats of lawsuits for CRNSV members as they attend meetings with major shareholders and potential partners who have demonstrated capability and patiently committed to address multiple gross deficiencies created by current management, typify the actions of a NYMOX management team of one individual. The leadership is presently in disarray and unable to function correctly as they again run out of funds.”
About The Committee to Restore Nymox Shareholder Value, LLC (CRNSV)
CRNSV was formed by former executives of the NYMOX PHARMACEUTICAL CORP ("NYMX-Q") with a goal to restore shareholder value in NYMOX (the Company). With a commitment to overcome the steep decline and volatility of the stock price following the catastrophic NASDAQ Delisting Decision, CRNSV has issued rebuttal letters to all Company shareholders and continues to emphasize lack of Company leadership, inability to realize the potential for valuable and promising results through a relationship with a highly respected global healthcare and specialty pharmacy solutions company; with expertise to help commercialize the Company’s benign prostatic hyperplasia (BPH) product, and Nymox’s lack of solution or plan for financial recovery of shareholder value. Headquartered in Carson City, Nevada with offices in London, CRNSV documents are available at https://www.crnsv.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230727625352/en/
Contact information
Chris Riley
info@crnsv.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The AI Summit London Launches Strategic Partnerships with London Business School and General Purpose to Ignite New Era in AI Leadership1.4.2026 10:00:00 EEST | Press release
The AI Summit London, the conference where commercial AI comes to life, has announced strategic collaborations with London Business School and General Purpose to introduce two dedicated AI Training programmes, taking place ahead of the conference on 9 June. Drawing upon the globally recognised expertise in executive education at the London Business School’s Data Science & AI Initiative (DSAI), the one-day AI Leadership Accelerator is a high-impact session designed to equip senior business leaders with the knowledge and tools to unlock real and profitable value from AI. The DSAI at London Business School helps leaders make sense of AI in a way that goes beyond the hype, focusing on what it really means for their organisations, industries, and competitive positioning. Drawing on rigorous, cross-disciplinary research, DSAI provides clear, evidence-based insights - equipping executives with the perspective needed to make confident, high-stakes decisions. “Through our work we increasingly s
Samsung Research Reveals Over Half of Europeans Admit to Looking at a Stranger's Phone Screen in Public – With Nearly a Quarter Doing so out of Sheer Curiosity1.4.2026 09:00:00 EEST | Press release
As millions of Europeans2 get ready to enjoy the Easter weekend, new research from Samsung finds Europe’s public spaces have become shared screens: 56% of people say they have accidentally looked at a stranger’s phone, citing public transport as the most likely place to notice someone else’s screen (57%). Nearly one in four Europeans2 (24%) admit to looking at someone else’s phone out of curiosity, exposing a stream of private content from personal photos to bank details. Samsung Electronics surveyed 11,000 Europeans2 to support the launch of the Galaxy S26 Ultra, which introduces a built-in Privacy Display. This new hardware-based technology keeps screen content visible only from the front to protect privacy from side angles, without compromising the viewing experience3. The study further reveals a gap between perceived phone privacy and reality: While 48%* feel their own phone use is private when using it in crowded places, 52%** find it easy to view someone else’s screen in public.
RevolKa Reimagines Antibody Engineering with "RevoAb ® "1.4.2026 07:30:00 EEST | Press release
RevolKa Ltd. (RevolKa), a venture-backed biotech company providing an advanced AI protein engineering technology platform, called aiProtein®, is pleased to announce the official global launch of RevoAb®, an innovative and quick online service for antibody sequence optimization to solve challenges in physicochemical properties, especially antibodyyields. RevoAb®:The Next-Gen AI Antibody Design Since December 2023, RevolKa has provided an antibody optimization services utilizing aiProtein®. The newly launched RevoAb® is a quick intuitive online antibody sequence optimization service that integrates RevolKa’s core technology—the "Refined Naturalness Framework Engineering". RevoAb® is designed to generate antibody framework sequences optimized for improved physicochemical properties, especially protein expression levels, without trade-off of affinity. This allows researchers worldwide to experience RevolKa’s high-performance antibody design. Key Advantages of RevoAb® Speed: Multiple optimi
Global Beauty Market Grows 10% as AI and E-commerce Reshape Consumer Buying1.4.2026 04:00:00 EEST | Press release
NielsenIQ (NYSE:NIQ), a global leader in consumer intelligence, today released its State of Beauty 2026 report, showing the global beauty market grew 10% year-on-year, with E-commerce expanding six times faster than in-store sales. The findings highlight a rapid shift to digital-first, AI-influenced commerce across key global markets. As consumer expectations evolve toward convenience, personalization, and seamless digital experiences, beauty brands are under increasing pressure to adapt. From AI-powered product discovery to social commerce and livestream shopping, the path to purchase is becoming more dynamic—requiring brands to move faster and engage consumers across an increasingly complex ecosystem. Key findings from the State of Beauty 2026 report: Global beauty sales grew 10% year-over-year, driven by strong digital acceleration E-commerce is growing 6x faster than in-store sales, reshaping channel strategies 49% of consumers are willing to pay more for locally made products, ref
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 20:01:00 EEST | Press release
TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet365 can lead with technical excellence by testing on real-world configurations that mirror its diverse global user base. Founded in 20
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom